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ercutaneous Transcatheter Aortic Valve
mplantation: Assessing Results, Judging
utcomes, and Planning Trials
he Interventionalist Perspective
aul T. L. Chiam, MBBS, MRCP, Carlos E. Ruiz, MD, PHD, FACC
ew York, New York
ortic valve stenosis is increasing in frequency as the population ages. Surgical aortic valve replace-
ent is the gold standard for symptomatic patients with severe aortic valve stenosis. However, in a
ubset of high-risk patients, the surgical option is excluded due to severe comorbidities. Recently, an
lternative to surgical aortic valve replacement—percutaneous aortic valve replacement (PAVR)—has
merged. Since the ﬁrst PAVR in a human in 2002, the percutaneous heart valves (PHVs) have already
ndergone several modiﬁcations from ﬁrst generation devices. Currently, there are 2 PHVs in clinical
pplication, a balloon-expandable and a self-expandable PHV, with several others achieving ﬁrst-in-
an application. With the extremely rapid technological advancements, PAVR is probably here to stay.
he next steps required would be to formulate goals to assess results and outcomes of PAVR, and plan
rials to test their clinical applicability. This article discusses how best to assess results and outcomes,
hich may require a paradigm shift in mindset. Apart from the randomized controlled trial, some of
he more novel concepts in trial design, which may be more suitable in this area, are also
xplored. (J Am Coll Cardiol Intv 2008;1:341–50) © 2008 by the American College of Cardiology
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hhe prevalence of aortic valve stenosis (AS) in-
reases with advancing age, and is present in 4.6%
f adults 75 years of age (1). With increasing life
xpectancy and an aging population, the number of
atients with AS will greatly increase (2). Once
ymptoms occur, the prognosis is poor (3). Surgical
ortic valve replacement (AVR), with an operative
ortality of 3% to 8%, is the treatment of choice
or the majority of these patients, with relief of
ymptoms and improved survival (4,5).
However, in a significant percentage of patients,
ainly the very elderly and those with severe
omorbidities, the risk of AVR is often considered
o be much higher, and these patients are, there-
rom the Department of Cardiac and Vascular Interventional Services,
enox Hill Heart and Vascular Institute, New York, New York. Dr.
uiz is a consultant to CoreValve.v
anuscript received January 29, 2008; revised manuscript received
arch 24, 2008, accepted March 28, 2008.ore, not offered surgery (4–8). Balloon aortic
alvuloplasty has a role in providing temporary
elief of symptoms (9,10), although the recurrence
ates are unacceptably high, with a 1-year survival
ate of only 54% to 75% (11–13). Its main role is
alliation or as a bridge to surgical AVR. Medical
herapy for these patients is associated with a
ismal outcome (14). Because of the limited ther-
peutic options in this subset of patients, there has
een interest in the development of a less invasive
VR strategy.
Recently, an alternative to surgical AVR—
ercutaneous aortic valve replacement (PAVR)—
as emerged. This was first demonstrated by
ndersen et al. (15) in 1992, who delivered a
orcine bioprosthesis attached to a wire-based
tent at various aortic sites with satisfactory
emodynamic results. Subsequently, other in-
estigators were able to perform catheter delivery
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342f bioprosthetic valves of various designs in animals
16–18).
The first human percutaneous valve replacement was
erformed by Bonhoeffer et al. (19) in 2000, where a
ercutaneous heart valve (PHV) made from bovine jugular
ein mounted on a platinum-iridium stent was successfully
laced in a stenotic right ventricle to pulmonary conduit
ith good results.
Two years later, Cribier et al. (20) reported the first
uccessful PAVR. Various groups have now reported their
arly experiences with the balloon-expandable and self-
xpandable PHVs (21–28). With the intense interest of the
nterventional cardiology community, technological ad-
ancements are being made exponentially. PAVR is prob-
bly here to stay, and highly likely a matter of time before it
becomes an effective option for
selected patients with severe
symptomatic AS and severe co-
morbidities. The next goal is to
plan trials, to assess the results,
and define clinical applications
for PAVR, assuming these trials
are favorable.
Current Status of
Aortic PHVs
Currently, there are 2 PHVs in
clinical trials, the balloon-
expandable Cribier-Edwards
(Edwards Lifesciences Inc., Ir-
vine, California) valve and, more
recently, the Edwards-Sapien
valve (Edwards Lifesciences
Inc.), and the self-expandable
CoreValve (CoreValve, Irvine,
California). The balloon-
expandable PHV consists of 3
pericardial leaflets initially
quine (Cribier-Edwards), and currently bovine (Edwards-
apien), mounted within a tubular, slotted, stainless steel
alloon-expandable stent (Fig. 1). Current generation de-
ices require either a 22-F or 24-F sheath for delivery
20,21,25,27,28). This PHV was initially implanted via the
ntegrade transseptal approach. There were several prob-
ems with this approach (21,24,28), and the retrograde
pproach has since been shown to be safer with the use of a
roprietary steerable delivery catheter. Because of the large
elivery system utilized, surgical repair of the vascular access
ite is required (25,27). There are currently on-going
andomized controlled trials (RCTs) using this PHV
PARTNER [Placement of AoRTic traNscathetER] US
bbreviations
nd Acronyms
S  aortic valve stenosis
VR  aortic valve
eplacement
ABG  coronary artery
ypass graft
DA  Food and Drug
dministration
V  left
entricle/ventricular
PC  Objective
erformance Criteria
AVR  percutaneous aortic
alve replacement
HV  percutaneous heart
alve
OL  quality of life
CT  randomized
ontrolled trial
TS  Society of Thoracic
urgeonsnd PARTNER EU trials). MThe self-expandable PHV (CoreValve) consists of 3
ericardial tissue leaflets, initially bovine and currently
orcine, mounted and sutured in a self-expandable nitinol
tent (Fig. 2). The stent frame is 50 mm, with the lower
inlet) portion having a high radial force to expand and
xclude the calcified aortic leaflets; the middle portion
arries the valve—the coaptation point of the leaflets is
ctually supra-annular—and is constrained to avoid ob-
tructing the coronary arteries; and the upper portion
outlet) is flared to fixate the stent in the ascending aorta
nd provide longitudinal stability. Early generation devices
equired 25-F sheaths; later devices incorporated porcine
ericardial tissue constrained within 21-F, and now 18-F
heaths (22,23,26). This PHV is implanted via the retro-
rade approach.
There are several other aortic PHVs that have already
one the first-in-man application, such as the Paniagua
HV of Endoluminal Technology Research (Miami, Flor-
da) (Fig. 3) (29), the Enable PHV of ATS (Minneapolis,
innesota) (3-F) (Fig. 4), the AorTx PHV of Hansen
Figure 1. Edwards-Sapien PHV
(Top) Bovine pericardium leaﬂets (blue arrowhead) sutured (expanded
polytetraﬂuoroethylene) (black arrow) onto a stainless steel stent frame
(blue arrow). (Bottom) Delivery catheter (Retroﬂex II, Edwards Lifesciences
Inc., Irvine, California) with valve loaded (black arrowhead). PHV  percu-
taneous heart valve.edical (Mountain View, California) (Fig. 5), the Direct
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343low PHV of Direct Flow Medical (Santa Rosa, California)
Fig. 6), the Lotus PHV from Sadra Medical (Campbell,
alifornia) (Fig. 7), the Perceval PHV from Sorin Group
Arvada, Colorado) (Fig. 8), and the Jena PHV from
enaValve Technology (Wilmington, Delaware) (Fig. 9)
Table 1). Furthermore, several other innovative devices are
urrently in the developmental stage or in pre-clinical
esting (30,31).
arget Patient Population
s with any medical procedure, the risk/benefit ratio of
ortic PHV implantation must be carefully considered. The
enefits provided by this novel procedure must be weighed
ventually against what is considered today the “gold stan-
ard”—surgical AVR. Bearing in mind, however, the excel-
ent track record of surgical AVR, it seems prudent to
nitially target those patients who are at high surgical risk
ue to severe comorbidities. Thus, the patients currently
nrolled in these studies are chosen based on a risk score,
uch as the EuroSCORE or Society of Thoracic Surgeons
STS) score (32,33). The other set of patients who may be
onsidered at present are those with a deteriorated aortic
ioprosthesis and deemed at high risk for surgical reopera-
ion, and this “valve-in-valve” concept has already been
eported (34). With technological advancements, it is ex-
ected that the ease of implantation will improve and
omplications will decrease. In order to consider lower risk
nd younger patients as candidates for this new technology,
dditional long-term durability data will be required before
dvocating this procedure as a possible substitute to surgical
VR.
Therefore, the target population will rapidly evolve, with
he speed of evolution depending on proven risk/benefit
atio derived from ongoing clinical trials. The complications
Figure 2. CoreValve PHV
A 12-F delivery catheter shaft (white arrow), 18-F delivery case, which con-
tains valve (black arrow) with a ﬂexible distal nose cone; opened valve
consisting of the lower (inlet) portion (small arrowhead), the constrained
middle portion to allow coronary perfusion (red arrow), and the upper
(outlet) portion (large arrowhead). PHV  percutaneous heart valve.xperienced with this new technology reflect the steepearning curve combined with the fact that these were early
evice designs (21,22,25–28), and with increased follow-up,
ther problems may emerge. Ideally, prospective data
hould be gathered serially from well-characterized popula-
ions, to validate the selection criteria for this procedure. These
ill evolve rapidly once the durability of the PHV is compa-
able to the surgically implanted valve and as the safety of
mplanting PHVs surpasses that of surgical techniques.
ssessing Results
ssessing results should primarily focus on the implantation
rocedure and the immediate performance of the PHV. The
riteria used to assess the results of surgical AVR should be
pplied to all PHVs. Newly implanted prostheses will
equire consistently accurate implantation in the correct
natomical position with relative ease. They should not
bstruct the coronary ostia, and remain in situ without
islodgement or embolization. Of critical importance is the
emodynamic performance of the PHVs. The residual
radient should not be greater than currently accepted for
urgical valve prostheses, with an acceptable effective valve
rifice area. In addition, there should not be significant
ransvalvular regurgitation, and there should be a tight seal
etween the native structures and the device to minimize
Figure 3. Paniagua PHV
(Top) Delivery catheter, which houses the balloon, stent, and valve. (Bot-
tom) Proprietary processing of bovine pericardium with a valve leaﬂet
thickness of 40 m (arrow). PHV  percutaneous heart valve.
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344aravalvular leaks. Valve function, hemodynamics, regurgi-
ation, and paravalvular leaks are best assessed by echocar-
iography since it can be easily and repeatedly performed
nd interpreted by the same observer. Criteria for differen-
iating between transvalvular regurgitation from paravalvu-
ar leak and assessing their severity using echocardiography
ave been well defined previously (35).
udging Outcomes
utcomes should be assessed from 2 different perspec-
ives—the objective outcomes after PHV implantation, and
he subjective component of quality-of-life (QOL) parameters.
bjective outcomes. PERIPROCEDURAL OUTCOME. This
ncompasses in-hospital and 30-day outcomes, which are
he main end points used in surgical AVR reports. Mortality
nd all major adverse cardiovascular, cerebral, and vascular
vents should be recorded and compared. In addition,
evice failure or device-related complication such as infec-
ion, hemolysis, and thrombocytopenia (22), should also be
lassified under major adverse events. Furthermore, careful
ttention should be made to ensure that there is no evidence
f prosthesis-patient mismatch, as prosthesis-patient mis-
atch, defined as an indexed effective orifice valve area0.8
m2/m2, is an independent predictor of cardiac events,
0-day and long-term mortality in patients undergoing
Figure 4. Enable PHV
Pericardial valve leaﬂets (black arrow) sutured onto a self-expandable niti-
nol frame (arrowhead) with pledgets providing support and ﬁxation (red
arrow). PHV  percutaneous heart valve.urgical AVR (36–38).HORT-TERM (UP TO 1 YEAR) OUTCOME. This is usually
aken to begin after 30 days up until 1 year after implant.
he PHV position and function should be assessed, as well
s left ventricular (LV) function and other hemodynamic
ndexes that reflect performance of the PHV. Echocardiog-
aphy is the imaging modality of choice today, since serial
easurements can be made easily and inexpensively, al-
hough it can be subjective with interobserver variability
39,40). Regional and global LV systolic function assessed
y tissue Doppler imaging have been shown to improve
mmediately after PHV placement (41). Echocardiography,
owever, may not be sufficiently accurate to account for
rostheses migration, and, therefore, other imaging tech-
ologies such as computed tomographic angiography may
e required.
Early experiences revealed that paravalvular leaks were
ot infrequent after aortic PHV implantation, although
ignificant leaks were uncommon (0%, 7%, and 15% inci-
ence of paravalvular leaks grade 3) (26–28). Paraval-
ular leaks were also common after surgical AVR, being
resent in 47% of patients in one study. However, 97% of
Figure 5. AorTx PHV
(Top) Delivery catheter with the valve crimped within. (Bottom) Pericardial
leaﬂets sutured (arrow) onto a self-expandable nitinol stent. PHV  percu-
taneous heart valve.
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345hese were mild or moderate, and did not change in severity
r affect LV indices over 5 years (35). Clinically, the patient
hould be assessed for symptom improvement by changes in
ew York Heart Association functional class, vascular
ccess site problems, and for other adverse events as defined
arlier in the text.
ONG-TERM (>1 YEAR) OUTCOME. In addition to the con-
inuing follow-up of the parameters previously discussed,
he long-term durability of the PHV needs to be estab-
ished. The long-term results may not be so crucial currently
s patients are at very high risk with expected high mortality
ates. However, with time, this procedure may become
uitable for those at lower risk, and survival duration will
ake on greater prominence. The current regulatory bench
esting requirements for surgically implanted aortic prosthe-
es may not be sufficient to predict durability or stability of
hese PHVs, given the immense number of covariates that
ay play a role. Valve migration is conceivable due to
ontinuous mechanical movement of the LV outflow tract
nd remodeling of the surrounding tissues (42). This con-
ern theoretically may possibly be reduced with the self-
xpandable PHV models due to their ability to adapt
eometrically if the conformation and the structure of the
urrounding tissues change over time (42). It is unclear,
owever, whether the self-expandable PHV models would
ead to a higher incidence of late aortic erosion and possible
upture (42). Furthermore, the long-term durability of these
tents under complex motion conditions will need to be
roven as there already are reports of valve stent fractures in
he pulmonary position (43), which resulted in symptom
Figure 6. Direct Flow PHV
The valve is constructed of 2 hydrophilic coated inﬂatable rings (yellow
arrows) with bovine pericardial tissue sutured in a noninﬂatable cylindrical
segment that anchors the aortic annulus (green arrow). The valve is con-
trolled with 3 control wires (blue) and is ﬁxed in position by using a per-
manent polymer to inﬂate the 2 inﬂatable rings. PHV  percutaneous heart
valve.ecurrence or stent embolization.UBJECTIVE OUTCOMES. In our zest to judge outcomes, it is
mperative that we do not constrain ourselves to assess
angible data, morbidity, and longevity but, more impor-
antly, also focus on QOL. It should not be forgotten that
he primary aim of any medical therapy is to make patients
eel better. Therefore, concise QOL parameters must be
ssessed. There are several QOL questionnaires available,
nd it is beyond the scope of this article to determine which
ethodology is most ideal (44). Although more subjective,
OL may be more important to the patient than the
Figure 7. Lotus PHV
(Top) Nitinol valve unsheathed but still attached to delivery catheter. (Mid-
dle) Valve after shortening with increase in radial strength; sealing mem-
brane of the valve (white arrow). (Bottom) Valve viewed from the aortic
surface with the locks seen (black arrow). PHV  percutaneous heart
valve.
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346bjective indices of mortality and morbidity. This is partic-
larly so if the treatment goal is to improve symptoms, and
f physiologic measures that correlate with a patient’s expe-
ience are unavailable or inadequate. There is a tendency to
ssume a robust link between physiologic measurements and
patient’s functional status and well-being, but unfortu-
ately these often prove misleading. Patients with similar
emodynamic AS profiles can have vastly different symptom
everity (45). Furthermore, changes in conventional mea-
ures of clinical status may only show weak or modest
orrelation with changes in QOL (46). Strict focus on
Figure 8. Perceval PHV
(Top) Self-expandable proprietary stent that approximates the shape of the
aortic root and sinuses (blue arrows), and the nonexpandable posts (black
arrow) that support the pericardial tissue valve. It has a double pericardial
sheet that enhances sealing against the native valve (large down-pointing
purple/grey arrow) to decrease paravalvular leaks. Note: Large vertical
up-pointing arrow signiﬁes direction of blood ﬂow. (Bottom) Valve
viewed from the aortic surface with probes through patent coronary ostia
(white arrows). cor.  coronaria; dx  dextra (right coronary artery);
PHV  percutaneous heart valve; sx  sinestra (left coronary artery).hysiologic measures may lead the physician to believe thathe treatment is beneficial, when, in fact, it does not change
he way patients feel.
Because these early trials enrolled patients with very high
urgical risk or those who were nonsurgical candidates,
utcomes must be stratified by condition severity with some
f the risk scores mentioned previously (e.g., logistic Euro-
CORE or STS score) (32,33,47–49). Any increment in
urvival and, perhaps more importantly, improvement in
OL would be meaningful for this high-risk population.
The outcomes of these trials should be compared not only
ith the current surgical AVR results, but also the transapi-
al route of implanting PHVs (50,51), and other innovative
urgical techniques such as implantation of an apico-aortic
onduit (52). We must keep in mind that most surgical
lternatives are, however, not required to be scrutinized by
ny regulatory agency for safety and efficacy, and, therefore,
ny anecdotal data derived from these reports may be
ifficult to compare.
pproval Process and Clinical Validation
he approval process and clinical validation involve pre-
linical testing consisting of device concept, in vitro testing
nd then in vivo (animal) testing. The new PHVs will
equire Failure Mode Effects and Criticality Analysis, and
isk/benefit relevant to the particular device. Once these
ave been established, the device will then be subjected to
linical validation.
Prosthetic heart valves have been implanted in the U.S.
ince the 1960s, and none have required RCTs by the Food
nd Drug Administration (FDA) for approval. The FDA
Figure 9. JenaValve PHV
A low-proﬁle, repositionable, nitinol, self-expandable stent with pericardial
leaﬂets. The upper portion (arrow) is ﬂared to ﬁxate and orient the valve
in the aortic sinus; the eyelets (arrowhead) secure the valve for delivery.
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347nstead relies on an Objective Performance Criteria (OPC)
eveloped through analysis of historical data (53,54) that
as facilitated by a standardized set of definitions of
omplications published by the American Association of
horacic Surgeons and the STS in 1987/1988. A require-
ent, however, for using simple OPC rates (percent per
ear) to summarize a complication is that its risk is constant
cross time. Therefore, if a complication is time related, this
onstant risk assumption does not hold (55). For example,
ength of follow-up would be critical in assessing structural
ailure of tissue heart valves (12 to 15 years?). Also, the
PC method depends on identifying all valve-related com-
lications, including those that cause death, so a high
utopsy percentage must be a pivotal requirement of the
tudy. Because there are no OPCs for these events (mortal-
ty and sudden death), it is important that fatal valve-related
vents be classified into the OPC category to which they
elong (55). For these reasons, the OPC approach may not
e appropriate for all medical devices, and will not work for
HVs since the risk of structural failure is not constant
cross time.
esigning Trials
or PAVR to become a viable alternative, the procedural
nd long-term outcomes must be better than medically
reated patients and not inferior to surgical AVR in patients
ith comparable risk scores.
There are now 6 published case series of patients under-
oing PAVR (21,22,25–28). Both the results of the
alloon- and self-expandable PHVs have been reported. A
otal of 181 patients have been studied (22,26–28). Patient
election was similar in all series. All patients had severe
ymptomatic AS, and were refused surgery after evaluation
y both the surgeon and cardiologist. In the 3 most recent
eries, PHV implantation was successful in 146 of 171
85%) patients, with a mean 30-day mortality of 13.5% (23
f 171 patients), compared with a predicted mortality of
20% (26–28). In those patients who had successful
Table 1. Percutaneous Heart Valve Technologies
Device Company Expansion Mechani
Sapien Edwards Balloon-expandable
CoreValve CoreValve Self-expandable
Paniagua Endoluminal Technologies Research Balloon-expandable and self-e
Enable ATS (3-F) Self-expandable
AorTx Hansen Medical Self-expandable
Direct Flow Direct Flow Medical Polymer-injected
Lotus Sadra Medical Self-expandable
Perceval Sorin Group Self-expandable
JenaValve JenaValve Technology Self-expandable
FIM first-in-man.mplantation, there was dramatic hemodynamic and clinical bmprovement, with early and midterm relief of heart failure.
lthough clinical stability was observed up to 24 months
27,28), assessment of long-term durability will require at
east 5 years of follow-up. From these data, it can be seen
hat currently only the highest-risk patients for conventional
urgical AVR have been studied.
To conduct trials assessing PAVR, the patient population
as to be rigorously defined. In this respect, the risk scores
s mentioned earlier have an important role in stratifying
atients (33,48,49). The European studies tend to use the
ogistic EuroSCORE (32). This uses the same risk factors as
he additive EuroSCORE, but is more accurate for predict-
ng mortality in combined coronary artery bypass graft
CABG) and valve surgery (56), and for individual risk
rediction in the very high risk, since the additive Euro-
CORE tends to underestimate risk in this group
32,48,49). The U.S. studies conversely tend to use the STS
core (33), although all current publications on PAVR used
he logistic EuroSCORE (22,25–28). The STS score was
eveloped using data for isolated CABG surgery only,
hereas the EuroSCORE database included 30% valve
perations. Both scores were validated during their devel-
pment (33,48,49), and both were subsequently validated
or isolated valve replacement (7,47,57). The EuroSCORE
as better accuracy in predicting perioperative mortality
fter CABG compared with the STS score, and is also
uperior to many other score systems (58–60). Recently,
owever, it was shown that, for isolated surgical AVR in
ery high-risk patients, the STS score most accurately
redicted perioperative and long-term mortality when com-
ared with both the logistic and additive EuroSCOREs, as
ell as the newer Ambler score developed and validated on
atients undergoing heart valve surgery (61,62).
Next, the correct risk/benefit ratio based on a balance
etween safety and effectiveness perceived for the reduction
n surgical risk and superiority over medical therapy will
eed to be established. And with the advent of the transapi-
al route of aortic PHV, PAVR must also now be shown to
Valve Material Stent Material FIM Clinical Trials
Pericardium Stainless steel 2002 Yes
Pericardium Nitinol 2004 Yes
able Pericardium Stainless steel and nitinol 2003 No
Pericardium Nitinol 2005 No
Pericardium Nitinol 2006 No
Pericardium Polymer 2006 No
Pericardium Nitinol 2007 No
Pericardium Nitinol 2007 No
Pericardium Nitinol 2007 Nosm
xpande superior or, at least, equivalent to this technique. The end
p
f
a
u
a
t
E
n
t
s
e
w
c
d
c
a
l
s
t
t
A
e
t
s
r
a
c
a
o
c
h
s
s
A
p
u
F
d
i
a
s
c
p
P
m
i
a
a
b
p
P
a
d
i
p
t
p
a
p
e
P
A
b
p
k
s
o
t
s
c
r
f
b
e
d
w
C
E
p
e
t
n
a
R
H
S
1
R
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 4 , 2 0 0 8
A U G U S T 2 0 0 8 : 3 4 1 – 5 0
Chiam and Ruiz
Percutaneous Aortic Valve Implantation
348oints must be appropriate and should include device
unction and durability, clinical efficacy (functional status
nd QOL), morbidity, and mortality.
Based on the encouraging early results of PAVR, RCTs
sing a balloon-expandable PHV comparing percutaneous
ortic PHV implantation with surgical AVR or medical
herapy are underway (PARTNER-US and PARTNER-
U). The FDA requires that the new PHVs be proven
oninferior to surgical AVR and superior to medical therapy
hrough an RCT. A position statement by 4 professional
ocieties involved with PAVR also recommended RCTs to
valuate this new technology (63). Randomizing patients
ith severe symptomatic AS to medical therapy raises
ertain ethical issues since prognosis with this modality is
ismal, with 50% mortality at 2 years (14,45). Achieving
linical equipoise with surgical AVR can also be problematic
s it pits a new and evolving technology with a steep
earning curve against a mature technique. Demonstrating
uperiority can require a large sample size when small
reatment benefits are anticipated. This is particularly per-
inent as the proportion of patients with severe symptomatic
S at high surgical risk would be small. Using composite
nd points can decrease sample size requirement, albeit at
he risk of limiting the subanalysis of individual components
ince events may not be of equal magnitude (e.g., death vs.
eoperation) (64). Utilizing noninferiority design with an
ppropriate delta will also reduce sample size, but it may
onfound the ability to determine true equivalence.
Several newer concepts in trial design, which have been
pproved for Investigational Device Exemption trials of
ther cardiovascular devices that permit more timely study
ompletion and expedite availability of innovative devices,
ave to be considered (65). Prospective adaptive trial de-
igns allow for modifications to some aspects (e.g., sample
ize) of the trial without penalty to the statistical analysis.
nother innovative method, the Bayesian trial design, can
rovide an advantage over the traditional and more often
sed frequentist model if certain conditions exist (65).
requentist methods draw conclusions by relying only on
ata produced in a given study whereas Bayesian methods
ntegrate available prior information (55). The Bayesian
pproach is, therefore, less rigid, obviates the need for fixed
ample sizes and one-time assessments, and is most useful in
linical studies where information is collected in an ongoing
rocess, and where repeated interim analyses are required.
rior distribution of the parameter(s) of interest, however,
ust be quantified (66). Despite this limitation, the Bayes-
an approach may facilitate analysis of a study of smaller size
nd/or shorter duration. This approach has been used for
pproval of prosthetic cardiac valves (e.g., analyzing throm-
oembolic event rates using information derived from older
rosthetic valves) and may prove helpful for evaluating
HVs (65,66).For non-RCTs, the use of a propensity score analysis may
llow more appropriate comparison of control to treatment
ata (65,67). This addresses imbalances between groups by
ncorporating confounders and other covariates into a model
redicting the probability of assignment to a particular
reatment. It can be used for adjustment or for matching
atients who have similar probabilities of receiving a ther-
py. Differences in outcomes between treated and untreated
atients with equal propensity scores provide a less biased
stimate of therapy effect.
ost-Marketing Surveillance
s the long-term function and durability of devices may not
e reliably extrapolated from the relatively short period of a
re-market study, monitoring the performance after mar-
eting approval is a valuable approach (68). Post-market
tudies can provide evidence for the safety and effectiveness
f a device, when it is used in the ‘real world’ rather than in
rials of healthcare provision. However, it is imperative that
uch studies meet acceptable standards. Many devices re-
eive approval from the FDA on condition that post-market
egistries are performed (69). This should be taken one step
urther with aortic PHVs, and compulsory registries should
e mandated for these new technologies. If not instigated
arly, a valuable opportunity to obtain rigorous long-term
urability and outcome data in the ‘real-world’ environment
ill be lost.
onclusions
ver since the first human aortic PHV implant, the field has
rogressed extremely rapidly. This is a critical period in its
volution, and whether PAVR would one day not only be a
herapeutic option in the normal risk cohort but become the
ext “gold standard” remains to be seen. The road is long
nd arduous, but the journey has begun.
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